

AMENDMENTS TO THE CLAIMS

1-69. (Canceled)

70. (Currently Amended) The A pharmaceutical composition according to claim 65 comprising a monovalent antibody fragment, which prevents the binding of von Willebrand factor (vWF) to human platelet glycoprotein Ib (GPIb) and binds *in vivo* to human platelet GPIb without incurring thrombocytopenia, and a pharmaceutically acceptable carrier, wherein the variable region of said fragment comprises SEQ ID NO: 4.

71. (Currently Amended) The A pharmaceutical composition according to claim 65 comprising a monovalent antibody fragment, which prevents the binding of von Willebrand factor (vWF) to human platelet glycoprotein Ib (GPIb) and binds *in vivo* to human platelet GPIb without incurring thrombocytopenia, and a pharmaceutically acceptable carrier, wherein said monovalent antibody fragment is obtained from a monoclonal antibody produced by the cell line deposited with the Belgian Coordinated Collections of Microorganisms, under accession number LMBP 5108CB.

72-79. (Canceled)

80. (Previously Presented) A monoclonal antibody produced by the cell line deposited with the Belgian Coordinated Collections of Microorganisms, under accession number LMBP 5108CB.

81. (Currently Amended) A cell line, capable of producing an antibody directed against GP1b GPIb deposited with the Belgian Coordinated Collections of Microorganisms, under accession number LMBP 5108CB.

82. (Currently Amended) A humanized antibody fragment derivable from the monoclonal antibody of claim 80, wherein said humanized antibody fragment binds GP1b GPIb.

83. (Canceled)

84. (Previously Presented) A monovalent antibody fragment which binds *in vivo* to human platelet GPIb and prevents the binding of von Willebrand factor to human platelet GPIb, wherein said monovalent antibody fragment is obtained from a monoclonal antibody produced by the cell line deposited with the Belgian Coordinated Collections of Microorganisms under accession number LMBP 5108CB.

85. (Previously Presented) A monovalent antibody fragment which binds *in vivo* to human platelet GPIb and prevents the binding of von Willebrand factor to human platelet GPIb, wherein said monovalent antibody fragment includes a variable region comprising SEQ ID NO:4.